A joint modeling approach to study the association between subject-level longitudinal marker variabilities and repeated outcomes
share
Women are at increased risk of bone loss during the menopausal transition; in fact, nearly 50% of women's lifetime bone loss occurs during this time. The longitudinal relationships between estradiol (E2) and follicle-stimulating hormone (FSH), two hormones that change have characteristic changes during the menopausal transition, and bone health outcomes are complex. However, in addition to level and rate of change in E2 and FSH, variability in these hormones across the menopausal transition may be an important predictor of bone health, but this question has yet to be well explored. We introduce a joint model that characterizes individual mean estradiol (E2) trajectories and the individual residual variances and links these variances to bone health trajectories. In our application, we found that higher FSH variability was associated with declines in bone mineral density (BMD) before menopause, but this association was moderated over time after the menopausal transition. Additionally, higher mean E2, but not E2 variability, was associated with slower decreases in during the menopausal transition. We also include a simulation study that shows that naive two-stage methods often fail to propagate uncertainty in the individual-level variance estimates, resulting in estimation bias and invalid interval coverage
READ FULL TEXT
